eFFECTOR Therapeutics Picks Up $40M For Cancer Treatments

San Diego-based eFFECTOR Therapeutics, a biopharmaceuticals startup focused on treatment of cancer, announced this morning that it has raised $40M in a Series B funding. The funding was led by Altitude Life Science Ventures and also included AbbVie Biotech Ventures, BioMed Ventures, Abingworth, Novartis Venture Fund, SR One, The Column Group, US Venture Partners, Astellas Ventures, Osage University Partners and Mission Bay Capital. eFFECTOR is led by Steve Worland, and is targeting treatment of solid tumors and lymphoma. More information »